Takeda Pharmaceutical Co. Ltd.
Congress has disclosed 3 buys and 0 sells of TAK (Takeda Pharmaceutical Co. Ltd.) in official financial disclosures, each linked to its original filing. A transparency record — not investment advice.
Activity Congressional Activity
Round-trip watch Still on the books
Members who disclosed buying TAK and have not disclosed selling, versus their own entry (the most recent disclosed buy). "Open" means no disclosed sale — never "still holds" — and the % is unrealised, on paper. Not investment advice.
| Member | Entry (last buy) | Entry price | Now | vs entry | Status |
|---|---|---|---|---|---|
| Alan Armstrong | 2026-03-30 | $18.27 | $20.92 | +14.5% | in profit |
Price as of 2026-11-02. Counted open while disclosed buys outnumber disclosed sells; tracks the price, not exact position size (amounts are ranges).
Legislation Related Legislation
Recent bills in this stock's sector (). Sector-level context from Congress.gov — a bill names a policy area, not this company specifically.
| Bill | Title | Policy area | Latest action |
|---|---|---|---|
| HR 10887 | Protecting Consumer Access to Generic Drugs Act of 2026 | Health | 2026-10-22 |
| HR 10874 | Medicare Low Income Subsidy Equality Act of 2026 | Health | 2026-10-22 |
| HR 10858 | CARE for Blood Cancer Act of 2026 | Health | 2026-10-22 |
| HR 10810 | National Patient Safety Board Act of 2026 | Health | 2026-10-15 |
| HR 10824 | Stroke Education and EMS Care Improvement Act of 2026 | Health | 2026-10-15 |
3 trades Recent Congressional Trades
Two things to watch per trade: the disclosure lag (how many days passed before the trade was made public) and the price move in that window (how the stock moved during those non-public days). A sell followed by a price drop, or a buy followed by a rise, means well-timed trading — visible here in the open. Note: the Score measures how notable a trade is, not whether it made money — the price move is shown for context and isn't part of it.
| Politician | Chamber | Type | Owner | Date | Disclosure lag | Price move in that window | Amount | Score | Source |
|---|---|---|---|---|---|---|---|---|---|
| Alan Armstrong | Senate | BUY | Self | 2026-03-30 | 113 days | -5.7% | $1K–$15K | 99.1 | ↗ eFD |
| Virginia Foxx | House | BUY | Joint | 2023-02-16 | 13 days | — | $1K–$15K 0.2% of NW |
94.6 | ↗ filing |
| Virginia Foxx | House | BUY | Joint | 2022-11-01 | 0 days | — | $1K–$15K 0.2% of NW |
98.8 | ↗ filing |
Corporate insiders · SEC Form 4 Insider Activity
What the company's own officers and directors did in TAK — open-market purchases and sales from SEC Form 4 filings (option exercises, grants and tax withholding are excluded). This is context for the congressional activity above, never a buy/sell signal, and the two datasets are kept separate on purpose. Does convergence mean anything? →
Of the congressional trades in TAK, 0 coincided with corporate insiders moving the same way within 60 days, and 0 with insiders moving the opposite way. This is co-occurrence only — whether it carries any edge is tested honestly on the convergence page.
| Date | Insider | Role | Type | Size | Source |
|---|---|---|---|---|---|
| 2026-09-14 | Duprey Lauren Rusckowski | C-suite | SELL | $640K | ↗ EDGAR |
| 2026-09-02 | Plump Andrew Stewart | C-suite | SELL 10b5-1 | $2.1M | ↗ EDGAR |
| 2026-08-19 | Plump Andrew Stewart | C-suite | SELL 10b5-1 | $363K | ↗ EDGAR |
| 2026-08-18 | Greenway Nicola Deidre Petal | C-suite | SELL | $235K | ↗ EDGAR |
| 2026-08-11 | Shannon Elaine Mary | Other | SELL | $357K | ↗ EDGAR |
| 2026-08-10 | Greenway Nicola Deidre Petal | C-suite | SELL | $17K | ↗ EDGAR |
| 2026-08-10 | Greenway Nicola Deidre Petal | C-suite | SELL | $589K | ↗ EDGAR |
| 2026-08-10 | Furney Natalie Anne Marie | Other | SELL | $528K | ↗ EDGAR |
| 2026-08-10 | Platford Giles Richard | C-suite | SELL | $532K | ↗ EDGAR |
| 2026-08-10 | Kim Julie So-Young | C-suite | SELL | $1.5M | ↗ EDGAR |
| 2026-08-10 | Greenway Nicola Deidre Petal | C-suite | SELL | $116K | ↗ EDGAR |
| 2026-08-10 | Ricci Gabriele | C-suite | SELL | $429K | ↗ EDGAR |
| 2026-08-10 | Shannon Elaine Mary | Other | SELL | $68K | ↗ EDGAR |
| 2026-08-10 | Bitetti Teresa Marie | C-suite | SELL | $855K | ↗ EDGAR |
| 2026-08-10 | Pignagnoli Agosti Marcello | Other | SELL | $393K | ↗ EDGAR |
| 2026-08-10 | Plump Andrew Stewart | C-suite | SELL | $2.8M | ↗ EDGAR |
| 2026-08-10 | Duprey Lauren Rusckowski | C-suite | SELL | $814K | ↗ EDGAR |
| 2026-08-10 | Pacheco Rhonda Janice | C-suite | SELL | $289K | ↗ EDGAR |
| 2026-08-10 | Ibrahim Ramy Riad Ahmed | C-suite | SELL | $124K | ↗ EDGAR |
| 2026-08-10 | Farajallah Awny Samaan Botros | C-suite | SELL | $240K | ↗ EDGAR |
| 2024-01-24 | TAKEDA PHARMACEUTICAL CO LTD | Other | SELL | $30.0M | ↗ EDGAR |
Combined timeline — Congress & insiders
Both sets of trades on one timeline, newest first, so you can see when they lined up. Congress vs ◆ insider.
| Date | Who | Type | Size | |
|---|---|---|---|---|
| ◆ insider | 2026-09-14 | Duprey Lauren Rusckowski C-suite | SELL | $640K |
| ◆ insider | 2026-09-02 | Plump Andrew Stewart C-suite 10b5-1 | SELL | $2.1M |
| ◆ insider | 2026-08-19 | Plump Andrew Stewart C-suite 10b5-1 | SELL | $363K |
| ◆ insider | 2026-08-18 | Greenway Nicola Deidre Petal C-suite | SELL | $235K |
| ◆ insider | 2026-08-11 | Shannon Elaine Mary Other | SELL | $357K |
| ◆ insider | 2026-08-10 | Greenway Nicola Deidre Petal C-suite | SELL | $17K |
| ◆ insider | 2026-08-10 | Greenway Nicola Deidre Petal C-suite | SELL | $589K |
| ◆ insider | 2026-08-10 | Furney Natalie Anne Marie Other | SELL | $528K |
| ◆ insider | 2026-08-10 | Platford Giles Richard C-suite | SELL | $532K |
| ◆ insider | 2026-08-10 | Kim Julie So-Young C-suite | SELL | $1.5M |
| ◆ insider | 2026-08-10 | Greenway Nicola Deidre Petal C-suite | SELL | $116K |
| ◆ insider | 2026-08-10 | Ricci Gabriele C-suite | SELL | $429K |
| ◆ insider | 2026-08-10 | Shannon Elaine Mary Other | SELL | $68K |
| ◆ insider | 2026-08-10 | Bitetti Teresa Marie C-suite | SELL | $855K |
| ◆ insider | 2026-08-10 | Pignagnoli Agosti Marcello Other | SELL | $393K |
| ◆ insider | 2026-08-10 | Plump Andrew Stewart C-suite | SELL | $2.8M |
| ◆ insider | 2026-08-10 | Duprey Lauren Rusckowski C-suite | SELL | $814K |
| ◆ insider | 2026-08-10 | Pacheco Rhonda Janice C-suite | SELL | $289K |
| ◆ insider | 2026-08-10 | Ibrahim Ramy Riad Ahmed C-suite | SELL | $124K |
| ◆ insider | 2026-08-10 | Farajallah Awny Samaan Botros C-suite | SELL | $240K |
| Congress | 2026-03-30 | Alan Armstrong | BUY | $1K–$15K |
| ◆ insider | 2024-01-24 | TAKEDA PHARMACEUTICAL CO LTD Other | SELL | $30.0M |
| Congress | 2023-02-16 | Virginia Foxx | BUY | $1K–$15K |
| Congress | 2022-11-01 | Virginia Foxx | BUY | $1K–$15K |
FAQ Common questions
How much has Congress traded TAK?
3 disclosed buys and 0 sells of TAK (Takeda Pharmaceutical Co. Ltd.) appear in official congressional financial disclosures.
Is it legal for members of Congress to trade TAK?
Members of Congress may trade stocks but must disclose it under the STOCK Act. QuantCapitol tracks those public disclosures for transparency — nothing here is an accusation of wrongdoing or investment advice.
Where does this data come from?
Official US House Clerk and Senate electronic financial disclosures. Every trade links back to its original filing so you can verify it yourself.